acyclovir and Bronchiectasis

acyclovir has been researched along with Bronchiectasis* in 2 studies

Other Studies

2 other study(ies) available for acyclovir and Bronchiectasis

Article	Year
Acute liver failure due to Varicella zoster virus infection after lung transplantation: a case report. Transplantation proceedings, 2012, Volume: 44, Issue:5 Most adults are Varicella zoster virus (VZV)-positive at the age of 20 years. Some, however, remain antibody-negative and may develop primary chicken pox during adulthood. We report a patient with Williams-Campbell syndrome who underwent double-lung transplantation while being VZV-negative. One year after the successful procedure, he was admitted with fulminant hepatic failure and some cutaneous vesicles in his face. Despite a rapid diagnosis of VZV infection and treatment with acyclovir, his situation deteriorated within 24 hours and while awaiting an urgent liver transplantation, he developed multiple organ failure and died. Topics: Acyclovir; Adult; Antiviral Agents; Bronchiectasis; Chickenpox; Fatal Outcome; Herpesvirus 3, Human; Humans; Liver Failure, Acute; Liver Transplantation; Lung Transplantation; Male; Multiple Organ Failure; Respiratory Insufficiency; Time Factors; Waiting Lists	2012
Valaciclovir for chronic hepatitis B virus infection after lung transplantation. Infection, 2004, Volume: 32, Issue:1 We report on a chronic asymptomatic hepatitis B surface antigen (HBsAg) carrier who developed an increase in aminotransferase and HBsAg levels 1 year after lung transplantation. During treatment for cutaneous herpes simplex virus (HSV) infection with oral valaciclovir there was a marked decrease in replicating hepatitis B virus (HBV)-DNA and aminotransferase levels, which was sustained for 9 months by continuing low-dose valaciclovir. A second rise in aminotransferase levels again responded to a valaciclovir dose increase and the HBV-DNA levels declined further. Although we cannot exclude a spontaneous variation of the serologic parameters, our observation suggests that valaciclovir may represent a valuable therapeutic option in the treatment of chronic hepatitis B after lung transplantation. Topics: Acyclovir; Bronchiectasis; Carrier State; Chronic Disease; Female; Follow-Up Studies; Graft Survival; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lung Transplantation; Middle Aged; Postoperative Complications; Preoperative Care; Risk Assessment; Serologic Tests; Treatment Outcome; Valacyclovir; Valine	2004

Article

Year

Acute liver failure due to Varicella zoster virus infection after lung transplantation: a case report.

Transplantation proceedings, 2012, Volume: 44, Issue:5

Most adults are Varicella zoster virus (VZV)-positive at the age of 20 years. Some, however, remain antibody-negative and may develop primary chicken pox during adulthood. We report a patient with Williams-Campbell syndrome who underwent double-lung transplantation while being VZV-negative. One year after the successful procedure, he was admitted with fulminant hepatic failure and some cutaneous vesicles in his face. Despite a rapid diagnosis of VZV infection and treatment with acyclovir, his situation deteriorated within 24 hours and while awaiting an urgent liver transplantation, he developed multiple organ failure and died.

Topics: Acyclovir; Adult; Antiviral Agents; Bronchiectasis; Chickenpox; Fatal Outcome; Herpesvirus 3, Human; Humans; Liver Failure, Acute; Liver Transplantation; Lung Transplantation; Male; Multiple Organ Failure; Respiratory Insufficiency; Time Factors; Waiting Lists

2012

Valaciclovir for chronic hepatitis B virus infection after lung transplantation.

Infection, 2004, Volume: 32, Issue:1

We report on a chronic asymptomatic hepatitis B surface antigen (HBsAg) carrier who developed an increase in aminotransferase and HBsAg levels 1 year after lung transplantation. During treatment for cutaneous herpes simplex virus (HSV) infection with oral valaciclovir there was a marked decrease in replicating hepatitis B virus (HBV)-DNA and aminotransferase levels, which was sustained for 9 months by continuing low-dose valaciclovir. A second rise in aminotransferase levels again responded to a valaciclovir dose increase and the HBV-DNA levels declined further. Although we cannot exclude a spontaneous variation of the serologic parameters, our observation suggests that valaciclovir may represent a valuable therapeutic option in the treatment of chronic hepatitis B after lung transplantation.

Topics: Acyclovir; Bronchiectasis; Carrier State; Chronic Disease; Female; Follow-Up Studies; Graft Survival; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Lung Transplantation; Middle Aged; Postoperative Complications; Preoperative Care; Risk Assessment; Serologic Tests; Treatment Outcome; Valacyclovir; Valine

2004